PFIZER INC
PFEAPI behind this page
PFE Q2 2025 request
Playground key active
/api/financials?ticker=PFE&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 11,954 | 10,871 | +10.0% |
| Royalty | 426 | 345 | +23.5% |
| Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer | 2,273 | 2,067 | +10.0% |
Show Product Lines breakouts |
|||
| Total Alliance revenues [Member] | 2,273 | 2,067 | +10.0% |
| Revenue | 14,653 | 13,283 | +10.3% |
Show Product Lines breakouts |
|||
| Abrysvo [Member] · Biopharma [Member] | 143 | 56 | +155.4% |
| Adcetris [Member] · Biopharma [Member] | 255 | 279 | -8.6% |
| All other Hospital [Member] · Biopharma [Member] | 1,087 | 1,146 | -5.1% |
| All other Oncology [Member] · Biopharma [Member] | 380 | 347 | +9.5% |
| All other Primary Care [Member] · Biopharma [Member] | 736 | 759 | -3.0% |
| All other Specialty Care [Member] · Biopharma [Member] | 390 | 429 | -9.1% |
| Aromasin [Member] · Biopharma [Member] | 111 | 87 | +27.6% |
| Bosulif [Member] · Biopharma [Member] | 149 | 167 | -10.8% |
| Braftovi/Mektovi [Member] · Biopharma [Member] | 182 | 148 | +23.0% |
| Cibinqo [Member] · Biopharma [Member] | 69 | 47 | +46.8% |
| Comirnaty [Member] · Biopharma [Member] | 381 | 195 | +95.4% |
| Cresemba [Member] · Biopharma [Member] | 111 | 71 | +56.3% |
| Eliquis [Member] · Biopharma [Member] | 2,003 | 1,877 | +6.7% |
| Elrexfio [Member] · Biopharma [Member] | 85 | 22 | +286.4% |
| Enbrel (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 154 | 179 | -14.0% |
| FSME-IMMUN/TicoVac [Member] · Biopharma [Member] | 109 | 100 | +9.0% |
| Genotropin [Member] · Biopharma [Member] | 106 | 119 | -10.9% |
| Ibrance [Member] · Biopharma [Member] | 1,049 | 1,130 | -7.2% |
| Inflectra [Member] · Biopharma [Member] | 139 | 97 | +43.3% |
| Inlyta [Member] · Biopharma [Member] | 243 | 252 | -3.6% |
| Lorbrena [Member] · Biopharma [Member] | 251 | 169 | +48.5% |
| Nurtec ODT/Vydura [Member] · Biopharma [Member] | 359 | 356 | +0.8% |
| Oncology Biosimilars [Member] · Biopharma [Member] | 353 | 279 | +26.5% |
| Padcev [Member] · Biopharma [Member] | 542 | 394 | +37.6% |
| Paxlovid [Member] · Biopharma [Member] | 427 | 251 | +70.1% |
| Pfizer CentreOne [Member] | 328 | 278 | +18.0% |
| Pfizer Ignite [Member] | 20 | 15 | +33.3% |
| Prevnar Family [Member] · Biopharma [Member] | 1,383 | 1,359 | +1.8% |
| Sulperazon (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 166 | 144 | +15.3% |
| Talzenna [Member] · Biopharma [Member] | 46 | 32 | +43.8% |
| Tivdak [Member] · Biopharma [Member] | 46 | 33 | +39.4% |
| Tukysa [Member] · Biopharma [Member] | 132 | 121 | +9.1% |
| Vyndaqel family [Member] · Biopharma [Member] | 1,615 | 1,323 | +22.1% |
| Xeljanz [Member] · Biopharma [Member] | 322 | 303 | +6.3% |
| Xtandi [Member] · Biopharma [Member] | 566 | 495 | +14.3% |
| Zavicefta (Outside the U.S. and Canada) [Member] · Biopharma [Member] | 163 | 150 | +8.7% |
| Zithromax [Member] · Biopharma [Member] | 56 | 74 | -24.3% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 14,305 | 12,991 | +10.1% |
| Biopharma [Member] · International Commercial Division [Member] | 5,512 | 5,163 | +6.8% |
| Biopharma [Member] · Oncology [Member] | 4,387 | 3,956 | +10.9% |
| Biopharma [Member] · Operating Segments | 14,305 | 12,991 | +10.1% |
| Biopharma [Member] · Primary Care [Member] | 5,540 | 4,952 | +11.9% |
| Biopharma [Member] · Specialty Care [Member] | 4,378 | 4,083 | +7.2% |
| Biopharma [Member] · U.S. Commercial Division [Member] | 8,793 | 7,828 | +12.3% |
Show Geography breakouts |
|||
| International Developed Markets [Member] | 3,393 | 3,164 | +7.2% |
| International Emerging Markets [Member] | 2,366 | 2,227 | +6.2% |
| US | 8,894 | 7,892 | +12.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 348 | 292 | +19.2% |
| Cost of Revenue | 3,778 | 3,300 | +14.5% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 3,075 | 2,411 | +27.5% |
| Selling, General & Administrative | 3,415 | 3,717 | -8.1% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2,305 | 2,473 | -6.8% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,482 | 2,696 | -7.9% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2,109 | 2,293 | -8.0% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 2 | 6 | -66.7% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 2 | 7 | -71.4% |
| Amortization Of Intangible Assets Not Associated With Single Function | 1,211 | 1,307 | -7.3% |
| Restructuring Charges And Acquisition Related Costs | -18 | 1,254 | -101.4% |
| Other Non-Operating Income (Expense) | 739 | 1,107 | -33.2% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | -115 | -90 | -27.8% |
| Income Before Taxes | 3,044 | -103 | +3055.3% |
Show Business Segments breakouts |
|||
| Biopharma [Member] | 6,929 | 5,897 | +17.5% |
| Biopharma [Member] · Operating Segments | 6,929 | 5,897 | +17.5% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -1,799 | -1,985 | +9.4% |
| Material Reconciling Items · Acquisition-Related Items [Member] | -338 | -617 | +45.2% |
| Material Reconciling Items · Amortization of Intangible Assets [Member] | -1,211 | -1,307 | +7.3% |
| Material Reconciling Items · Certain Significant Items [Member] | -537 | -2,091 | +74.3% |
| Income Tax Expense (Benefit) | 141 | -134 | +205.2% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 2,903 | 31 | +9264.5% |
| Income Loss From Discontinued Operations Net Of Tax | 25 | 17 | +47.1% |
| Net Income | 2,928 | 48 | +6000.0% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 18 | 7 | +157.1% |
| Parent | 2,910 | 41 | +6997.6% |
| Retained Earnings | 2,910 | 41 | +6997.6% |
| Net Income Loss Attributable To Noncontrolling Interest | 18 | 7 | +157.1% |
| Net Income | 2,910 | 41 | +6997.6% |
| Income Loss From Continuing Operations Per Basic Share | 0.51 | 0.01 | +5000.0% |
| EPS (Basic) | 0.51 | 0.01 | +5000.0% |
| Income Loss From Continuing Operations Per Diluted Share | 0.51 | 0.01 | +5000.0% |
| EPS (Diluted) | 0.51 | 0.01 | +5000.0% |
| Wtd Avg Shares (Basic) | 5,685 | 5,666 | +0.3% |
| Wtd Avg Shares (Diluted) | 5,706 | 5,696 | +0.2% |
| Interest Income | -156 | -130 | -20.0% |
| Comprehensive Income | 3,053 | -17 | +18058.8% |
| Net Income Loss Available To Common Stockholders Basic | 2,910 | 41 | +6997.6% |
| Interest Expense | 654 | 778 | -15.9% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,638 | 1,052 | +55.7% |
| Accounts Receivable | 12,078 | 11,393 | +6.0% |
| Inventory | 11,669 | 11,447 | +1.9% |
| Other Tax Assets Current | 4,016 | 3,694 | +8.7% |
| Other Assets Current | 2,690 | — | — |
| Total Current Assets | 43,703 | 37,825 | +15.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 18,776 | 18,957 | -1.0% |
| Goodwill | 68,997 | — | — |
| Deferred Tax Assets Net And Other Tax Assets Noncurrent | 10,343 | 7,867 | +31.5% |
| Other Non-Current Assets | 9,455 | 10,710 | -11.7% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Fair Value Measurements Recurring | 1,009 | 1,246 | -19.0% |
Show Fair Value By Measurement Frequency breakouts |
|||
| Fair Value Measurements Recurring | 1,009 | 1,246 | -19.0% |
| Total Assets | 206,095 | 216,193 | -4.7% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Fair Value Measurements Recurring | 1,118 | 2,210 | -49.4% |
| Fair Value Inputs Level2 · Fair Value Measurements Recurring | 12,503 | 7,112 | +75.8% |
Show Fair Value By Measurement Frequency breakouts |
|||
| Fair Value Measurements Recurring | 13,621 | 9,322 | +46.1% |
| Intangible Assets | 34,028 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 32,629 | — | — |
| License Agreements and Other [Member] | 1,137 | — | — |
| Trade Names | 262 | — | — |
| Long Term Investments | 2,120 | 11,149 | -81.0% |
| Other Assets | |||
| Other Short Term Investments | 11,611 | 6,048 | +92.0% |
| Equity Method Investments | 224 | — | — |
| Other Long Term Investments | 1,896 | 3,119 | -39.2% |
| Intangible Assets Net Excluding Goodwill | 52,702 | — | — |
| Current Liabilities | |||
| Debt Current | 4,295 | 11,944 | -64.0% |
| Accounts Payable | 5,166 | 5,106 | +1.2% |
| Dividends Payable Current | 2,445 | 2,380 | +2.7% |
| Taxes Payable Current | 3,675 | 2,884 | +27.4% |
| Employee Related Liabilities Current | 2,447 | 2,566 | -4.6% |
| Deferred Revenue (Current) | 1,123 | 2,528 | -55.6% |
Show Product Lines breakouts |
|||
| Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] | 1 | 2.5 | -60.0% |
| Other Liabilities Current | 18,575 | 16,410 | +13.2% |
Show Product Lines breakouts |
|||
| Comirnaty [Member] · BioNTech [Member] | 94 | — | — |
| Total Current Liabilities | 37,726 | 43,819 | -13.9% |
| Current Portion of Long-Term Debt | 4,246 | 3,745 | +13.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 57,502 | 57,506 | -0.0% |
Show Long-Term Debt Type breakouts |
|||
| Unsecured Debt | 57,502 | 57,506 | -0.0% |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 2,130 | 2,040 | +4.4% |
| Deferred Tax Liabilities | 2,481 | 2,227 | +11.4% |
| Liability For Uncertain Tax Positions Noncurrent | 3,313 | 6,532 | -49.3% |
| Other Non-Current Liabilities | 13,931 | 16,095 | -13.4% |
| Total Liabilities | 117,083 | 128,218 | -8.7% |
| Long-Term Debt (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign currency long-term debt [Member] | 878 | 799 | +9.9% |
| Contract With Customer Liability Noncurrent (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Paxlovid and Comirnaty [Member] · Government and Government Sponsored [Member] | 906 | 1.8 | +50233.3% |
| Other Liabilities | |||
| Minority Interest | 317 | 275 | +15.3% |
| Stockholders' Equity | |||
| Common Stock | 481 | 480 | +0.2% |
| Additional Paid-In Capital | 94,053 | 93,197 | +0.9% |
| Treasury Stock Common Value | -115,010 | -114,757 | -0.2% |
| Retained Earnings | 117,609 | 116,596 | +0.9% |
| Accumulated Other Comprehensive Income | -8,438 | -7,816 | -8.0% |
| Total Stockholders' Equity | 88,695 | 87,700 | +1.1% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 89,012 | 87,975 | +1.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Net Prior Service Cost Credit | 115 | 84 | +36.9% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -589 | -77 | -664.9% |
| Accumulated Net Unrealized Investment Gain Loss | 75 | -1 | +7600.0% |
| Accumulated Other Comprehensive Income | -8,438 | -7,816 | -8.0% |
| Accumulated Translation Adjustment | -8,040 | -7,822 | -2.8% |
| Additional Paid In Capital | 94,053 | 93,197 | +0.9% |
| Common Stock | 481 | 480 | +0.2% |
| Noncontrolling Interest | 317 | 275 | +15.3% |
| Parent | 88,695 | 87,700 | +1.1% |
| Retained Earnings | 117,609 | 116,596 | +0.9% |
| Treasury Stock Common | -115,010 | -114,757 | -0.2% |
| Total Liabilities & Equity | 206,095 | 216,193 | -4.7% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 3,243 | 3,467 | -6.5% |
Show Business Segments breakouts |
|||
| Biopharma [Member] · Operating Segments | 671 | 667 | +0.6% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 147 | 177 | -16.9% |
| Material Reconciling Items · Acquisition-Related Items [Member] | -3 | 2 | -250.0% |
| Material Reconciling Items · Amortization of Intangible Assets [Member] | 2,421 | 2,615 | -7.4% |
| Material Reconciling Items · Certain Significant Items [Member] | 7 | 5 | +40.0% |
| Asset Write Offs And Asset Impairment Charges | 498 | 431 | +15.5% |
| Deferred Income Taxes | -935 | -1,224 | +23.6% |
| Stock-Based Compensation | 373 | 426 | -12.4% |
| Pension And Other Postretirement Benefit Contributions Net Of Pension And Other Postretirement Benefit Expense | -334 | -338 | +1.2% |
| Other Non-Cash Items | -61 | 260 | -123.5% |
| Increase Decrease In Operating Capital | -6,908 | -6,871 | -0.5% |
| Net Cash from Operations | 1,753 | -691 | +353.7% |
| Investing Activities | |||
| Capital Expenditures | -1,182 | -1,341 | +11.9% |
| Payments To Acquire Short Term Investments | -6,085 | -1,254 | -385.2% |
| Proceeds From Sale Maturity And Collection Of Shortterm Investments | 10,500 | 1,712 | +513.3% |
| Payments For Proceeds From Short Term Investments With Original Maturities Of Three Months Or Less | -2,668 | 3,538 | -175.4% |
| Payments To Acquire Marketable Securities | -86 | -108 | +20.4% |
| Proceeds From Sale Maturity And Collection Of Longterm Investments | 145 | 312 | -53.5% |
| Proceeds From Sale Of Equity Method Investments | 6,311 | 3,491 | +80.8% |
| Other Investing Activities | 288 | -18 | +1700.0% |
| Net Cash from Investing | 7,225 | 6,332 | +14.1% |
| Financing Activities | |||
| Repayments Of Short Term Debt | -2,199 | -4,852 | +54.7% |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -903 | -1,101 | +18.0% |
| Proceeds From Issuance Of Long Term Debt | 3,687 | — | — |
| Repayments Of Long Term Debt | -3,750 | -2,250 | -66.7% |
| Payments Of Ordinary Dividends | -4,882 | -4,752 | -2.7% |
| Proceeds From Payments For Other Financing Activities | -377 | -449 | +16.0% |
| Net Cash from Financing | -8,423 | -7,390 | -14.0% |
| Supplemental | |||
| Income Taxes Paid | 3,493 | 2,686 | +30.0% |
| Interest Paid | 1,483 | 1,553 | -4.5% |
| Interest Paid Received Interest Rate Hedges | 29 | -2 | +1550.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 34 | -46 | +173.9% |
| Net Change in Cash | 588 | -1,794 | +132.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,694 | 1,123 | +50.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.